Kilsoo Kang, CEO of Deargen “Development of AI-specialized new drugs… Promotion of cooperation with global pharmaceutical companies”

The first company that applied “Transformer” technology grafted onto biology, had attended as a thesis predicting the treatment effect of remdesivir on coronavirus. Made collaboration with SK Chemicals and Handok… Establishing own 4D program, pipeline. Also, will increase the research rate on rare diseases through ‘bio-type open source’”